CSS
CBIO

Cubist Systematic Strategies’s Crescent Biopharma CBIO Stock Holding History

Cubist Systematic Strategies’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-138
Closed -$3.43K – 3085
2024
Q4 		$3.43K Buy
+138
New +$3.76K ﹤0.01% 2887
2024
Q2 		– Sell
-498
Closed -$149K – 3365
2024
Q1 		$149K Buy
+498
New +$149K ﹤0.01% 3179
2023
Q2 		– Sell
-449
Closed -$56.6K – 3812
2023
Q1 		$56.6K Sell
449
-34
-7% -$7.65K ﹤0.01% 3548
2022
Q4 		$146K Buy
+483
New +$71.2K ﹤0.01% 3704
2021
Q2 		– Sell
-269
Closed -$81K – 2973
2021
Q1 		$81K Buy
269
+103
+62% +$36.9K ﹤0.01% 2680
2020
Q4 		$62K Buy
+166
New +$58.2K ﹤0.01% 2449
2018
Q4 		– Sell
-51
Closed -$74K – 2143
2018
Q3 		$74K Buy
+51
New +$77.1K ﹤0.01% 1650
2018
Q2 		– Sell
-33
Closed -$54K – 1877
2018
Q1 		$54K Buy
+33
New +$68.6K ﹤0.01% 1693

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cubist Systematic Strategies's CBIO Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Crescent Biopharma (CBIO) in Q1 2025, closing a stake of 138 shares — an estimated $3.43K sold.

Cubist Systematic Strategies first reported a position in CBIO in Q1 2018 and held it in 8 quarters. The position peaked at $149K in Q1 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Crescent Biopharma position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 138 Crescent Biopharma shares in Q1 2025, an estimated $3.43K.
  • Cubist Systematic Strategies first reported a position in Crescent Biopharma in Q1 2018 and held it in 8 quarters.
  • Cubist Systematic Strategies's Crescent Biopharma position peaked at $149K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.